Disclaimer

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.
2016 Results Highlights

- **Revenue**: USD389.9m, 6.6%↑YOY;
- **Net Profit**: turnaround from (USD$11.4m) in 2015 to USD15.1m in 2016
- Higher than market average growth rate in the core segments:
  - Cardiovascular: 11.8%↑YOY, among which Firehawk 127%↑YOY, 115%↑YOY from China market and 212%↑YOY from overseas market
  - Endovascular: 24%↑YOY; Neurovascular: 20%↑YOY; Electrophysiology: 28%↑YOY
  - China Joints sector: 32%↑YOY
- **MPO**: further narrowed its net loss with cash flow break-even achieved
- **MPSC selected as Shenzhen-Hong Kong Stock Connect Eligible Stock from March 2017**

All Growth Rates Excluding Foreign Exchange Impact
### CARDIO
- Firesorb™ completed FIM; 6 & 12-month results released
- Firesorb™ was granted CFDA Green Path
- VitaFlow™ was granted CFDA Green Path, and completed enrollment of pre-market clinical trial
- Firehawk™ was approved in Brazil, India, Argentina, Vietnam, Pakistan, South Korea, and Mexico
- Firehawk™ TARGET AC Postmarket Clinical Trial completed patient enrollment

### ENDO
- Minos™ completed patient enrollment of pre-market clinical trials
- Castor™ was granted CFDA Green Path, and completed CFDA regulatory submission
- Minos™ was granted CFDA Green Path
- Reewarm™ drug-coated balloon was granted CFDA Green Path
- Hercules™ and Reewarm™ obtained CE mark

### EP
- Flashpoint Renal Artery RF Ablation Catheter was granted CFDA Green Path
- Columbus® 3D EP Navigation System obtained CFDA approval
- FireMagic® Cool 3D obtained CFDA approval
- FireMagic® Cool Catheter obtained CFDA approval
- 8 products were approved in Argentina, Brazil and South Korea

### NEURO
- Tubridge™ was granted CFDA Green Path, and completed CFDA regulatory submission
- APOLLO™ in large sizes obtained CFDA approval
- FireMagic® Cool 3D obtained CFDA approval
- WILLIS® was admitted into Shanghai’s Drug Reimbursement List

### ORTHO
- EVOLUTION Revision Tibia obtained CFDA approval
- Medial-Pivot Knee Post-market Clinical Follow-up Program
- WILLIS® was approved in Thailand
- WILLIS® was admitted into Shanghai’s Drug Reimbursement List

### CRM
- BonaFire® Pacing Leads completed the first implantation in the First-in-Man clinical trial

### SURGICAL ROBOT
- Significant progress was achieved in the development of 3D laparoscope and surgical robot
Financing and Investment

- USD15m with certain investors in LB’s stock and convertible debt (CB), diluted ownership in LB of ~49.1%, assuming conversion of CB
- Distribution rights for Altura and Aorfix in China and Brazil
- Reduce the manufacturing costs of Aorfix and Altura to improve the GM of LB by leveraging MPEV’s expertise

- USD3 million investment for ~13.3% ownership in MinInvasive
- 5 year Distribution Agreement for greater China territory (China, HK, Macau)
- 5 years supply agreement for GSC to provide components for OmniCuff for global demand
- 5 year Manufacturing Agreement for OmniCuff’s sales in China

- Net proceeds raised from the transactions is approximately RMB396 m
- MicroPort’s ownership in MPEV is 61.79% after the transaction
- Optimized MicroPort’s balance sheet for funding future growth
- Introduced strategic partners for MPEV
1. Annual Results Highlights

2. Financial Review

3. Business Review

4. Outlook

5. Appendix
   - Financial Statements
Consolidated Financial Performance

Group revenue up 7% excl. FX, 4% as reported

Operating Expenses*

Gross Margin improved 3 percentage points

Net Profit/(Loss)

Percentage of sales improved 4 percentage points

Turnaround from loss ($11.4m) to profit $15.1m.

* Includes R&D costs, distribution costs, and administrative expenses
Cashflow Summary

Net Cashflow from Operating Activities

USD: million

2015: 31
2016: 83

\[\uparrow 52 \text{m}\]

Net operating cash inflow increased significantly by $52m, reflecting the strength of our underlying business

Net Cashflow from Investing Activities*

USD: million

2015: 47
2016: 85

\[\uparrow 38 \text{m}\]

Net investing cash outflow increased $38m to support business growth

Net Cashflow*

USD: million

2015: (181)
2016: 26

\[\uparrow 297 \text{m}\]

Net cashflow turned positive to $26m in 2016

Convertible bond issued in 2016 bringing in Carlyle as new important strategic investor

* Includes movement in pledged deposits and time deposits (2016: -2m vs 2015: -69m)

*2015 includes (160m) Otsuka loan repayment

• Cashflow excludes impact from foreign exchange translation
• Includes movement in pledged deposits and time deposits (2016: -2m vs 2015: -69m)
1. Annual Results Highlights

2. Financial Review

3. Business Review

4. Outlook

5. Appendix
   - Financial Statements
### Orthopedics Business – Non-China Ortho

#### Revenue (Non-China Ortho)

- **Under Wright**
  - 2011: 300 million
  - 2012: 267 million
  - 2013: 223 million
  - 2014: 204 million
  - 2015: 196 million
  - 2016: 200 million

- **Under MicroPort**
  - 2015: 204 million
  - 2016: 200 million

#### Net Loss

- **2015**: (33) million
- **2016**: (19) million

#### Operating Cash Flow

- **2015**: 14 million
- **2016**: (10) million

### Revenue By Geographic Area

- **US**:
  - 2015: 88 million USD
  - 2016: 88 million USD

- **EMEA**:
  - 2015: 58 million USD
  - 2016: 59 million USD

- **Japan**:
  - 2015: 31 million USD
  - 2016: 30 million USD

- **Others**: 2015: 21 million USD, 2016: 23 million USD

#### Key Points

- **Continued to build our corporate brand around the concept of Full Function, Fast Recovery™** to promote our differentiated products.
- **Non-China Ortho continued to deliver solid financial performance**
  - First time in 7 years achieved growth on topline
  - Reached positive cash flow and EBITDA
  - Further narrowed its net loss to USD$19.4 million
  - GP% improved from 58.5% in 2015 to 60.4% in 2016
- **US and Europe**: maintained a steady growth pace
- **Japan**: revenue declined by 4.5% in 2016 vs. 14% in 2015, a significant deceleration of revenue decline
- **ROW**: increased by 11.4%, strong growth in Australia
1. Orthopedics Business – China Business

- **China OrthoRecon**: Robust Growth Rate of 32% YOY, Higher than Market Average Growth Rate
  - Solid ramp up on Superpath™ and Evolution™
  - Focused on product R&D and further improvement of medical solutions
  - Domestically made joint product ready for facility inspection by government authorities

- **Global Supply Center ("GSC")**: Supplied 49% of our global orthopedic instrument and improve the cost structure of Ortho
  - Achieved initial success in the integration of the global supply chain for orthopedic instruments
  - Continued to reduce costs for our global orthopedic business
  - Started to diversify by offering value-added service

- **Instrument Manufacturing**:
  - Completion of verification, start to fulfill GSC orders

---

**Revenue and Growth**

<table>
<thead>
<tr>
<th></th>
<th>USD: million Excl. FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Ortho</td>
<td>+17% 9.1</td>
</tr>
<tr>
<td>Joints</td>
<td>+32% 7.1</td>
</tr>
<tr>
<td>GSC</td>
<td>+396% 11.1</td>
</tr>
</tbody>
</table>

**2016 Superpath™ and Evolution™ in China**

**Hospital Coverage**

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>SuperPath</td>
<td>12</td>
<td>99</td>
</tr>
<tr>
<td>Evolution</td>
<td>7</td>
<td>20</td>
</tr>
</tbody>
</table>

**Superpath™ Surgical Cases**

<table>
<thead>
<tr>
<th></th>
<th>Y2015</th>
<th>Y2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>739</td>
<td>1332</td>
</tr>
</tbody>
</table>

31-Dec-14 31-Dec-15 31-Dec-16

**Before consolidation**

- SuperPath +32%
- Evolution +80%

---

*Note: All data is presented in USD (million Excl. FX), and growth rates are calculated before consolidation.*
2. Cardiovascular Business

Global Cardiovascular Revenue

<table>
<thead>
<tr>
<th>Year</th>
<th>USD: million Adjusted Excl. FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>98</td>
</tr>
<tr>
<td>2011</td>
<td>112</td>
</tr>
<tr>
<td>2012</td>
<td>116</td>
</tr>
<tr>
<td>2013</td>
<td>111</td>
</tr>
<tr>
<td>2014</td>
<td>102</td>
</tr>
<tr>
<td>2015</td>
<td>123</td>
</tr>
<tr>
<td>2016</td>
<td>138 (11.8%)</td>
</tr>
</tbody>
</table>

Domestic DES Sales Growth by Products

<table>
<thead>
<tr>
<th>Year</th>
<th>USD: million Excl. FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>108</td>
</tr>
<tr>
<td>2013</td>
<td>100</td>
</tr>
<tr>
<td>2014</td>
<td>86</td>
</tr>
<tr>
<td>2015</td>
<td>96</td>
</tr>
<tr>
<td>2016</td>
<td>97 (26)</td>
</tr>
</tbody>
</table>

Total: 14.8% ↑

Firehawk: 127% ↑

Percentage of Firehawk in Domestic DES sales

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue % of FH in FB2+FH</th>
<th>Sales Volume % of FH in FB2+FH</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>11%</td>
<td>6%</td>
</tr>
<tr>
<td>2016</td>
<td>21%</td>
<td>12%</td>
</tr>
</tbody>
</table>

Highlights

- **Revenue** increased by 11.8% excl. FX or 4.1% in USD
- **Domestic stents** achieved revenue growth of 14.8%
- **Firehawk™** achieved an impressive sales growth rate of 127% and covers 331 hospitals in 27 provinces, representing 94.7% growth from 2015 domestically.
- **Firebird2™** sales maintained an organic growth and covers 1,254 hospitals in 30 provinces in China, representing an increase of 8.5% compared to 2015.
- **Firehawk™** unit volume and revenue accounted for 12% and 21% of overall DES sales
2. Cardiovascular Business - International business

### Overseas DES Revenue

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Firebird</td>
<td>5.7</td>
<td>5.3</td>
</tr>
<tr>
<td>Firehawk</td>
<td>1.7</td>
<td>5.3</td>
</tr>
</tbody>
</table>

USD: million Excl. FX

+ 40%  
+ 212%

- **Firehawk™** available for sale in 27 countries, 17 more than 2015, and its sales revenue more than tripled than 2015.
- **Firehawk™** Target AC clinical trial met its objective to recruit and enroll a total of 1,656 patients in 21 sites in 10 countries, successfully accomplishing this objective in 10 months which was four months ahead of plan.
- **Firehawk™** launched its IDE project in 2016, paving the way for USFDA pre-market submission.

### New Countries & Distributors Development

- **1656 pts randomized**
- **21 sites**

### Firehawk™ TARGET AC Enrollment Status

- Total 27 countries, increased 17 countries in 2016
3. Endovascular Business

**Revenue (USD million Excl. FX)**

- 2010: 8.1
- 2011: 8.8
- 2012: 10.2
- 2013: 12.1
- 2014: 13.1
- 2015: 15.3
- 2016: 18.9

**Sales growth by products**

- **HT**: +19% 8.8
- **HBL**: +44% 0.9
- **HBB**: +71% 1.3
- **AB**: +26% 1.4
- **surgical**: +11% 3.6

**Highlights**

- **MPEV maintains leadership position in domestic Endo market**
  - Achieved YOY sales growth of 24% excl. FX and 17% in USD, exceeding market average level
- **Hercules Thoracic Stent-Graft System**
  - Maintains strong growth momentum with 50% volume and 37% growth rate in volume and revenue, respectively.
- **Cronus™ Surgical stent graft system**
  - Unique product adopted in China, maintained solid growth since launch over one decade ago.
- **MicroPort Endovascular products**
  - Cover 546 hospitals, 17% more than 2015, among which 102 was newly entered in 2016.
- **Reewarm™ PTX Drug Coated Balloon**
  - Financing of MPEV was granted Green-Path
- **Extensive product pipeline**
  - ~17 products expected by 2019 across all sectors

**Product Name**

- Castor™
- Reewarm™ 18 Peripheral Balloon Dilatation Catheter
- Minos™ Ultra Low Profile AAA Stent-Graft
- Reewarm™ PTX Drug Coated Balloon
- Fontus Brachiocephalic Stent Graft System
- Talos New-generation Thoracic Stent-Graft System
4. Neurovascular Business

**Revenue**

<table>
<thead>
<tr>
<th>Year</th>
<th>USD: million Excl. FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>2.0</td>
</tr>
<tr>
<td>2011</td>
<td>2.6</td>
</tr>
<tr>
<td>2012</td>
<td>3.1</td>
</tr>
<tr>
<td>2013</td>
<td>4.3</td>
</tr>
<tr>
<td>2014</td>
<td>5.8</td>
</tr>
<tr>
<td>2015</td>
<td>7.4</td>
</tr>
<tr>
<td>2016</td>
<td>8.8</td>
</tr>
</tbody>
</table>

**Sales growth by products**

<table>
<thead>
<tr>
<th>Products</th>
<th>USD: million Excl. FX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apollo</td>
<td>4.5</td>
</tr>
<tr>
<td>Willis</td>
<td>6.0</td>
</tr>
</tbody>
</table>

**Highlights**

- Revenue growth by 19.5% excl. FX or 12.5% in USD
- Robust growth momentum maintained for APOLLO since launch over one decade ago with growth rate of 33% yoy
- WILLIS® is the only CFDA approved stent-graft for the treatment of intracranial aneurysm
- WILLIS® included in Shanghai’s Drug Reimbursement List with 80% expense covered by insurance
- WILLIS® obtained regulatory approval in Thailand
- Tubridge™ granted Green-Path for CFDA approval
- APOLLO™ in large sizes received CFDA approval in January 2017
### Highlights

- The only Chinese company to have 3-D Magnet Mapping System and full EP product line.
- Revenue growth of 28.1% excl. FX or 19.7% in USD.
- Columbus® and FireMagic™ 3D Cool & Supercool obtained CFDA Approval.
- Sales revenue of FireMagic™ Cardiac RF Ablation Catheter and EasyFinder™ Fixed Curve Diagnostic Catheter increased by 15% and 25% yoy, respectively.
- Sales revenue from overseas market grew 16%.
- EP business was approved by HKSE and the Board for quotation on NEEQ.
- EP products were sold to Greece, Turkey, Pakistan and Dominican Republic and successfully entered in five hospitals in Turkey in 2016.
- EP products covered 214 hospitals in China, 12% more than 2015.

### Sales Growth by Products

<table>
<thead>
<tr>
<th>Year</th>
<th>RF diagnostic catheter-quadrupole</th>
<th>RF diagnostic catheter-ten pole</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>0.9</td>
<td>0.8</td>
</tr>
<tr>
<td>2016</td>
<td>1.2</td>
<td>0.9</td>
</tr>
</tbody>
</table>

+15% increase in RF diagnostic catheter-quadrupole from 2015 to 2016.

+33% increase in RF diagnostic catheter-ten pole from 2015 to 2016.

+13% increase in RF diagnostic catheter-quadrupole from 2015 to 2016.
Appendix 1 - Business Highlights

Appendix 2 - Financial Statements

Contents
1. Annual Results Highlights
2. Financial Review
3. Business Review
4. Outlook
5. Appendix
   - Financial Statements
Outlook

- **FIRESORB**
  - FUTURE II Clinical Trial expected to launch in the third quarter of 2017;
  - Firesorb®’s CFDA approval expected to be received by 2020

- **TAVI**
  - VitaFlow™ Transcatheter Aortic Valve and Delivery System expected to obtain CFDA approval in 2018;
  - VitaFlow™ R Transcatheter aortic valve and re-sheathable delivery system expected to launch clinical trial in China, and complete feasibility analysis of CE registration by end 2017

- **ORTHO**
  - Domestically made knee products and hip products expected to obtain CFDA approval in 2018 and 2019, respectively

- **ENDO**
  - Castor™ and Reewarm™ expected to obtain CFDA approval in 2017;
  - Reewarm™ will complete patient enrollment for its pre-market clinical trial;
  - The component manufacturing collaboration between Lombard Medical and MPEV to be executed in 2017

- **NEURO**
  - Tubridge™ Vascular Reconstruction Device is expected to gain CFDA approval by end of 2017;
  - 6 products are under research

- **CRM**
  - Domestically made pacemaker has completed animal experiment and in preparation for CFDA approval.
## Appendix I

### - Consolidated Income Statement

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
<th>Flux %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td>389,921</td>
<td>375,844</td>
<td>4%</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>(118,243)</td>
<td>(123,335)</td>
<td>-4%</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>271,678</td>
<td>252,509</td>
<td>8%</td>
</tr>
<tr>
<td>Other revenue &amp; net gain</td>
<td>20,677</td>
<td>15,525</td>
<td>33%</td>
</tr>
<tr>
<td>Research and development costs</td>
<td>(51,897)</td>
<td>(60,354)</td>
<td>-14%</td>
</tr>
<tr>
<td>Distribution costs</td>
<td>(128,464)</td>
<td>(127,739)</td>
<td>1%</td>
</tr>
<tr>
<td>Administrative expenses</td>
<td>(64,245)</td>
<td>(65,031)</td>
<td>-1%</td>
</tr>
<tr>
<td>Other operating costs</td>
<td>(1,818)</td>
<td>(4,886)</td>
<td>-63%</td>
</tr>
<tr>
<td><strong>Operating Profit</strong></td>
<td>45,931</td>
<td>10,024</td>
<td>358%</td>
</tr>
<tr>
<td>Finance costs</td>
<td>(16,704)</td>
<td>(14,778)</td>
<td>-13%</td>
</tr>
<tr>
<td>Share of losses of a joint venture</td>
<td>(3,941)</td>
<td>(3,788)</td>
<td></td>
</tr>
<tr>
<td><strong>Profit/(loss) before taxation</strong></td>
<td>25,286</td>
<td>(8,542)</td>
<td>-396%</td>
</tr>
<tr>
<td>Income tax</td>
<td>(10,217)</td>
<td>(2,837)</td>
<td>260%</td>
</tr>
<tr>
<td><strong>Net profit/(loss)</strong></td>
<td>15,069</td>
<td>(11,379)</td>
<td>-232%</td>
</tr>
</tbody>
</table>
## Consolidated Balance Sheet

<table>
<thead>
<tr>
<th></th>
<th>31 Dec 2016</th>
<th>31 Dec 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed assets</strong></td>
<td>270,243</td>
<td>271,203</td>
</tr>
<tr>
<td><strong>Intangible assets</strong></td>
<td>68,152</td>
<td>60,217</td>
</tr>
<tr>
<td>Prepayments for fixed assets</td>
<td>2,010</td>
<td>2,711</td>
</tr>
<tr>
<td><strong>Goodwill</strong></td>
<td>54,458</td>
<td>55,463</td>
</tr>
<tr>
<td>Interest in associate</td>
<td>11,432</td>
<td>-</td>
</tr>
<tr>
<td>Interest in joint venture</td>
<td>676</td>
<td>4,759</td>
</tr>
<tr>
<td>Available-for-sale financial assets</td>
<td>2,000</td>
<td>-</td>
</tr>
<tr>
<td><strong>Deferred tax assets</strong></td>
<td>4,739</td>
<td>3,711</td>
</tr>
<tr>
<td><strong>Other non-current assets</strong></td>
<td>3,364</td>
<td>4,339</td>
</tr>
<tr>
<td><strong>Total non-current assets</strong></td>
<td>417,074</td>
<td>402,403</td>
</tr>
<tr>
<td><strong>Inventories</strong></td>
<td>100,863</td>
<td>101,840</td>
</tr>
<tr>
<td>Trade and other receivables</td>
<td>128,752</td>
<td>126,957</td>
</tr>
<tr>
<td>Deposits with banks and investments</td>
<td>668</td>
<td>2,976</td>
</tr>
<tr>
<td>Cash and cash equivalents</td>
<td>123,694</td>
<td>99,467</td>
</tr>
<tr>
<td><strong>Derivative financial assets</strong></td>
<td>3,499</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>357,476</td>
<td>331,240</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>774,550</td>
<td>733,643</td>
</tr>
<tr>
<td><strong>Trade and other payables</strong></td>
<td>(96,858)</td>
<td>(99,423)</td>
</tr>
<tr>
<td>Interest-bearing borrowings</td>
<td>(108,456)</td>
<td>(55,086)</td>
</tr>
<tr>
<td>Income tax payable</td>
<td>(4,621)</td>
<td>(1,226)</td>
</tr>
<tr>
<td>Derivative financial liability</td>
<td>(23)</td>
<td>(397)</td>
</tr>
<tr>
<td>Obligation under finance leases</td>
<td>(81)</td>
<td>(1,209)</td>
</tr>
<tr>
<td><strong>Other current liabilities</strong></td>
<td>-</td>
<td>(7,260)</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td>(210,039)</td>
<td>(164,601)</td>
</tr>
<tr>
<td>Interest-bearing borrowings</td>
<td>(40,085)</td>
<td>(129,374)</td>
</tr>
<tr>
<td>Convertible bonds</td>
<td>(147,769)</td>
<td>(94,815)</td>
</tr>
<tr>
<td>Deferred income</td>
<td>(24,231)</td>
<td>(22,086)</td>
</tr>
<tr>
<td><strong>Other payables</strong></td>
<td>(2,664)</td>
<td>(1,574)</td>
</tr>
<tr>
<td><strong>Deferred tax liabilities</strong></td>
<td>(3,283)</td>
<td>(3,365)</td>
</tr>
<tr>
<td><strong>Total non-current liabilities</strong></td>
<td>(216,032)</td>
<td>(251,214)</td>
</tr>
<tr>
<td><strong>Share capital</strong></td>
<td>(14)</td>
<td>(14)</td>
</tr>
<tr>
<td><strong>Reserves</strong></td>
<td>(332,895)</td>
<td>(312,505)</td>
</tr>
<tr>
<td><strong>Non controlling interests</strong></td>
<td>(13,570)</td>
<td>(5,309)</td>
</tr>
<tr>
<td><strong>Total equity</strong></td>
<td>(346,479)</td>
<td>(317,828)</td>
</tr>
<tr>
<td><strong>Total liabilities and equity</strong></td>
<td>(774,550)</td>
<td>(733,643)</td>
</tr>
</tbody>
</table>
## Appendix III

- **Condensed Consolidated Cash Flow Statement - Adjusted**

<table>
<thead>
<tr>
<th>(USD '000)</th>
<th>2016</th>
<th>2015</th>
<th>Flux %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash generate from operations</td>
<td>89,875</td>
<td>36,132</td>
<td>149%</td>
</tr>
<tr>
<td>Income tax paid</td>
<td>(7,341)</td>
<td>(5,412)</td>
<td>36%</td>
</tr>
<tr>
<td><strong>Net cash from operating activities</strong></td>
<td>82,534</td>
<td>30,720</td>
<td>169%</td>
</tr>
<tr>
<td>Net cash from investing activities</td>
<td>(85,119)</td>
<td>(47,177)</td>
<td>80%</td>
</tr>
<tr>
<td>Net cash from financing activities</td>
<td>28,137</td>
<td>(164,952)</td>
<td>-117%</td>
</tr>
<tr>
<td><strong>Net movement in cash and cash equivalent</strong></td>
<td>25,552</td>
<td>(181,409)</td>
<td>-114%</td>
</tr>
<tr>
<td>Cash and cash equivalents at 1 January*</td>
<td>102,443</td>
<td>287,721</td>
<td>-64%</td>
</tr>
<tr>
<td>Effect of foreign exchange rate changes</td>
<td>(3,634)</td>
<td>(3,869)</td>
<td>-6%</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at 31 December</strong></td>
<td><strong>124,362</strong></td>
<td><strong>102,443</strong></td>
<td><strong>21%</strong></td>
</tr>
</tbody>
</table>

* Cash and cash equivalents balance includes pledged deposits and time deposits, of which was USD 668k as at 31st Dec 2016 (USD 2,976k as at 31st Dec 2015)
Thank You

The Patient Always Comes First